Aortic aneurysm, including both abdominal aortic aneurysm and thoracic aortic aneurysm, is the cause of death of 1% to 2% of the Western population. This review focuses only on thoracic aortic aneurysms and dissections. During the past decade, the genetic contribution to the pathogenesis of thoracic aortic aneurysms and dissections has revealed perturbed extracellular matrix signaling cascade interactions and deficient intracellular components of the smooth muscle contractile apparatus as the key mechanisms. Based on the study of different Marfan mouse models and the discovery of several novel thoracic aortic aneurysm genes, the involvement of the transforming growth factorβ signaling pathway has opened unexpected new avenues. Overall, these discoveries have 3 important consequences. First, the pathogenesis of thoracic aortic aneurysms and dissections is better understood, although some controversy still exists. Second, the management strategies for the medical and surgical treatment of thoracic aortic aneurysms and dissections are becoming increasingly gene-tailored. Third, the pathogenetic insights have delivered new treatment options that are currently being investigated in large clinical trials. (Circ Res. 2013;113:327-340.)
A ortic aneurysm and dissections account for 1% to 2% of all deaths in the Western countries, 1 and the incidence of thoracic aortic aneurysm (TAA) is ≈10.4 per 100 000 personyears. 2 Furthermore, because acute aortic dissections might be disguised as heart attacks, true incidence numbers could be significantly higher. 3 Aortic aneurysms are categorized into 2 main groups depending on their location: TAAs and abdominal aortic aneurysms. Abdominal aortic aneurysms are the most common group and are linked to various lifestyle-associated risk factors, including hyperlipidemia, hypertension, sex, and age. However, smoking is generally regarded as the most important risk factor. 4, 5 Heritability estimates as high as 70% have been found, and recently, several genes and loci have been associated with abdominal aortic aneurysms (DAB2IP, LRP1, CDKN2B-AS1, CNTN3, LPA, IL6R, and the sortilin-1 [SORT1] locus). [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In this review, we focus on TAA, which have an even stronger genetic component, with 20% of patients having a positive family history. 16, 17 This number is also likely to be underestimated because developing TAA usually remain asymptomatic. TAA can develop at the ascending (60%) or descending aorta (40%), the aortic arch (10%), or the upper abdomen (10%). 18 These numbers do not add up to 100% because patients with TAA experience aneurysms at >1 of these locations.
Life expectancy is mainly determined by the risk of aortic dissection. The main predictor of aortic dissection is the aortic diameter. 19, 20 Historically, aortic diameters >5.5 cm are regarded as at high risk for dissection. Aortas with a diameter >6 cm have a 3.6% risk of rupture, and 10.8% of such patients die because of dissection within a year. 21 Recent studies demonstrated that aortic diameter significantly correlates with age, weight, and sex and should be adjusted as such. 22 Several studies have developed reference values, expressed as Z scores, for children and adults. 23, 24 Recent findings suggest that the risk for aortic dissection is also determined by the specific underlying gene defect. As such, treatment strategies are increasingly tailored according to the underlying genetic cause.
In many TAA cases, a typical histopathologic finding of the aortic wall is observed, which previously was referred to as cystic medial necrosis, but is now more accurately called medial degeneration. Medial degeneration is not the cause of a dissection, but rather a consequential pathological finding or a side effect caused by a primary syndrome. 25 Medial degeneration is characterized by disruption of the lamellar organization of elastic fibers, accumulation of basophilic ground substance with cyst-like lesions, degradation of the extracellular matrix (ECM), including elastin fragmentation and disruptions of collagen, and apoptosis of vascular smooth muscle cells (VSMC). 25 In patients with TAA undergoing surgery, the prevalence of medial degeneration is 6%, whereas it rises up to 100% after having undergone combined aortic and aortic valve surgery. 25, 26 Although it is clear that excessive matrix degradation is involved in the development of TAA, the exact underlying mechanisms are not yet fully unraveled. One possible hypothesis focuses on matrix metalloproteinases (MMPs). 18 MMPs are zinc endopeptidases that can degrade the ECM of aortic tissue. 27 An imbalance between MMPs and their inhibitors, possibly caused by an excess of reactive oxygen species, could induce medial degeneration and aneurysm development. 28, 29 In addition, some chronic conditions, such as systemic arterial hypertension, can lead to thickening and fibrosis of the intimal layer and degradation and apoptosis of VSMC in the media, resulting in wall stiffness and weakness, and eventually in dissections and ruptures. 2 During the past 2 decades, it has become clear that genetic factors lie at the basis of TAA formation. Important progress has been made since the discovery of fibrillin-1 (FBN1) as the causal gene for Marfan syndrome. 30 The study of this human syndromic form of TAA and its counterpart in mouse has served as a paradigm for a better understanding of TAA in general and revealed the transforming growth factor (TGF)-β signaling pathway as a key culprit in the pathogenesis of TAA. Several other syndromic aneurysmal conditions (Loeys-Dietz syndrome [LDS], arterial tortuosity syndrome, autosomal recessive cutis laxa) and numerous additional genes have been identified and confirmed a strong basis for the dysregulation of TGF-β signaling as the common final pathway in aortic aneurysm development. Most interestingly, these findings have led to putative new therapeutic strategies for patients with TAA. This exciting story is further elaborated in the upcoming pages of this review.
Study of Syndromic TAA: A Key Role for TGF-β Signaling
The Marfan Syndrome
The Marfan syndrome (MFS; Online Mendelian Inheritance in Man 154700) is an autosomal dominant connective tissue disorder, with a prevalence of 2 to 3 per 10 000 individuals. 31 It is a multisystemic disorder affecting the skeletal (disproportionate overgrowth, joint laxity, vertebral column deformity), ocular (lens dislocation and myopia), and cardiovascular system (aortic root aneurysm and dissection, mitral valve disease). 32 Other symptoms include dural ectasia, striae distensae, recurrent inguinal hernias, pneumothorax, and lung emphysema. The cardiovascular manifestations cause the most important morbidity and mortality in patients with MFS. In the majority of patients with MFS, the primary dilatation occurs at the aortic root at the level of the sinuses of Valsalva. To facilitate the clinical diagnosis of MFS, first the Berlin, 33 later the Ghent, 34 and most recently the revised Ghent nosology 35 have been proposed. These guidelines, formulated by international experts in the field, facilitate the accurate recognition of MFS and the differential diagnosis with other TAA syndromes, thereby improving patient management, follow-up, and counseling. Four possible scenarios can lead to a diagnosis of MFS in a proband: aortic root dilatation (Z score >2) and ectopia lentis, aortic root dilatation with an FBN1 mutation, aortic root dilatation with sufficient systemic findings (score of ≥7 on the systemic scale; for details see Loeys et al 35 ) , or finally ectopia lentis with an FBN1 mutation that has been previously associated with aortic root dilatation. The causative gene of MFS, FBN1, encoding fibrillin-1 ( in 1991. 30 More than 1500 FBN1 mutations spread throughout the entire 65 exon-containing gene have been described ever since. 30, 32, 36, 37 FBN1 molecules assemble into microfibrils, which have an important structural function, both in the aortic wall and in the ciliary apparatus supporting the ocular lens. 38 This knowledge has supported for a long time the weak tissue model, which hypothesized that FBN1 mutations cause a purely structural deficiency. Weakening of the connective tissues and hence weakening of the aortic wall would make it prone to ruptures, 39, 40 whereas weakening of the ciliary apparatus caused ectopia lentis. However, the weak tissue model never provided a sufficient explanation for the skeletal overgrowth, and this challenged the idea of a pure structural role for fibrillin-1. A new vision on the pathogenesis of MFS was developed through the study of MFS mouse models (Online Table I ), specifically of the lung phenotype. 41 The hypothesis that FBN1 mutations might have adverse effects on the functioning of the latent TGF-β-binding protein (LTBP) complexes, because LTBP and FBN1 proteins were known interaction partners, [42] [43] [44] formed the basis of these experiments. Investigation of the developmental impairment of the pulmonary alveolar septation in the Fbn1 tm1Rmz mouse model (alias Fbn1 mgΔ ) demonstrated that fibrillin-1 deficiency alters matrix sequestration of the TGF-β latent complex, leading to uncontrolled release of TGF-β and as a consequence activation of the TGF-β pathway (Figure) . Most interestingly, the increased TGF-β signaling could be prevented by perinatal administration of a polyclonal TGF-β neutralizing antibody. 41 The findings of dysregulated TGF-β signaling were later confirmed through the study of the mitral valve prolapse phenotype 45 and the aortic aneurysmal phenotype, 46 both in the Fbn1 C1039G transgenic mouse. Originally, only the canonical (mothers against decapentaplegic homolog 4 [drosophila] [SMAD]dependent) TGF-β pathway was evaluated in aneurysmal disease, but more recently it became clear that the noncanonical (SMAD-independent) TGF-β pathway is also associated with aneurysm formation. 47 The latter involves signaling through the mitogen-activated protein kinases (MAPK), including the extracellular signal-regulated kinase (ERK)1/2, p38, and the Jun N-terminal kinase (Figure) .
The LDS
In 2005, a new syndrome, related to MFS, was described and designated as LDS (OMIM 609192 and OMIM 608967; Table 1 ). 52 In its most typical presentation, LDS is characterized by a triad of hypertelorism, cleft palate or bifid uvula, and arterial tortuosity, combined with widespread aneurysms. The aortic aneurysms tend to be more aggressive than in patients with MFS, leading to dissection and rupture at smaller diameters and at younger ages. 52 Additional MFS-like cardiovascular, craniofacial, and skeletal symptoms are often observed. Distinguishing features between LDS and MFS include hypertelorism, clef palate/bifid uvula, craniosynostosis, cervical spine instability, arterial tortuosity, and aneurysm beyond the aortic root. Although initially 2 types of LDS were distinguished, they are now thought to be part of a continuum of disease. LDS type 1 patients present with typical craniofacial features, whereas LDS type 2 patients lack the craniofacial features, but present with skin abnormalities, including frail and velvety skin. 72 Patients with LDS experience increased risk for aneurysms and dissections of other vessels, including cerebral aneurysms. 73 This illustrates the necessity of broad clinical follow-up in patients with LDS. On average, patients with LDS type 1 undergo cardiovascular surgical interventions AAA indicates abdominal aortic aneurysm; AD, autosomal dominant; AR, autosomal recessive; ASD, atrial septal defect; BAV, bicuspid aortic valve; CAD, coronary artery disease; EDS, Ehlers-Danlos syndrome; FTAAD, familial thoracic aortic aneurysm and dissection; GI, gastrointestinal tract; GOF, gain of function; LDS, Loeys-Dietz syndrome; LOF, loss of function; MFS, Marfan syndrome; PDA, patent ductus arteriosus; SKI, v-ski avian sarcoma viral oncogene homolog; SVAS, supravalvular aortic stenosis; TAA, thoracic aortic aneurysm; TGF, transforming growth factor; VSD, ventricular septal defect; and XL, X-linked.
*For COL1A1 mutations related to osteogenesis imperfecta, see Online Table II . †Other genes responsible for Moya-Moya disease have been identified (see OMIM252350 for review).
at younger ages and tend to have shorter life spans than LDS type 2 patients if untreated. 52 Medial degeneration in patients with LDS is often more diffuse with more collagen deposition, elastic fiber fragmentation, and glycosaminoglycan deposition. 25 Based on the findings of TGFBR2 mutations in MFS-like patients 74, 75 and the similarities of the human clinical phenotype and an existing conditional Tgfbr2 knockout mouse model with cleft palate, calvarial defects, and outflow tract defects, TGFBR2 was suggested as a candidate gene for LDS. [76] [77] [78] Indeed, mutations in both genes encoding the TGF-β receptors 1 and 2 (TGFBR1/2) were identified. Most LDS mutations are missense mutations found in the serine/threonine kinase domain of both receptors, 75, 79 which suggests loss of function as the relevant mechanism of pathogenesis. These findings provided further proof of the association between TAA and dysregulated TGF-β signaling (Figure) . 79 In addition to LDS and MFS-like patients, TGFBR1/2 mutations have also been described in familial TAA and dissection (FTAAD) families. 80 The large majority of patients with TGFBR1/2 mutations do not fulfill the diagnostic criteria for MFS, but rare exceptions with aortic aneurysm and ectopia lentis have been described. 75 Recently, 2 additional LDS genes have been identified: SMAD3 53 and TGFB2 54, 81 (Table 1) . SMAD3 mutations were initially described in the aneurysm-osteoarthritis syndrome, which is, based on the many clinical similarities (hypertelorism, bifid uvula, arterial tortuosity) with LDS, now also classified as LDS type 3. 53,82 SMAD3 is the first intracellular downstream effector of the TGF-β pathway. Similar to other receptor (R-)SMADs (including SMAD1, 2, 5, and 8), it is activated by phosphorylation by the type 1 TGF-β receptor. Further signalization and translocation to the nucleus are achieved through the formation of heteromeric complexes with comediator SMAD proteins, such as SMAD4. 83 Most interestingly, despite the loss-of-function SMAD3 mutations, the overall effect was an increase of TGF-β signaling as evidenced by increased pSMAD2 immunohistochemical staining of aortic wall tissues (Figure) . 82 MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; MLCK, myosin light chain kinase; MMP, matrix metalloproteinase; PAI, plasminogen activator inhibitor; TAK, transforming growth factor-β-activated kinase; TGF, transforming growth factor; TGFBR, transforming growth factor-β receptor; and TSP, thrombospondin.
Identification of causal TGFB2 mutations in patients with LDS 54,81 implicated for the first time the involvement of a TGF-β ligand in the development of TAA ( Table 1 ). The clinical phenotype of TGFB2 mutant patients demonstrates both features of MFS and LDS, including aortic aneurysm, mitral valve disease, club foot, bifid uvula, and skeletal features. TGFB2 is 1 of the 3 TGF-β cytokines. These are all highly expressed in the cardiovascular system, both during embryonic development and adult life, 84 and are kept in a latent state in the ECM. Haploinsufficient Tgfb2 mice recapitulated the human phenotype with aortic dilatations (aortic annulus and root), which were observed around the age of 8 months (Online Table I ). 54, 77 Western blot and immunohistochemical analysis of aortic wall tissues revealed a signature of increased canonical (pSMAD2) and noncanonical (phosphorylated extracellular signal-regulated kinase) signaling pathways (Figure) .
Disorders Related to MFS and LDS
Shprintzen-Goldberg syndrome (OMIM 182212) is characterized by craniosynostosis, skeletal changes (arachnodactyly, camptodactyly, scoliosis, joint hypermobility), and aortic aneurysms. Shprintzen-Goldberg syndrome shows a considerable phenotypic overlap with MFS and LDS but presents with additional manifestations, including mental retardation and severe skeletal muscle hypotonia. 85, 86 Very recently, v-ski avian sarcoma viral oncogene homolog (SKI) was identified as the causal gene for this rare TAA syndrome (Table 1) . 55, 87 The oncogene SKI encodes a protein that plays an important role in the negative feedback loop of the TGF-β signaling pathway (Figure) . SKI itself cannot bind to DNA, but SKI and the SKI-related protein SKI-like homolog are able to regulate transcription by competing with other transcription factors. SKI and SKI-like homolog bind to the SMAD3/SMAD4 complex, which subsequently binds to DNA and cause repression of transcription of TGF-β-responsive genes. The aneurysm phenotype in Shprintzen-Goldberg syndrome is less penetrant and less severe in comparison with that observed in MFS and LDS, possibly because of the temporal and regional expression pattern of SKI.
Aortic aneurysmal disease has been linked to altered TGF-β signaling in 2 other rare recessive connective tissue disorders: autosomal recessive cutis laxa type 1B and arterial tortuosity syndrome (Table 1 ). Both disorders are characterized by arterial tortuosity and aneurysms and share skin and skeletal findings with MFS and LDS. 88 Autosomal recessive cutis laxa type 1B (OMIM 614437) is caused by mutations in the EFEMP2 gene, 56 coding for fibulin-4 (FBLN4), a molecule involved in elastic fiber assembly and highly expressed in the medial layers of blood vessel walls, including the aortic media. FBLN4 and LTBP1 bind with high affinity, which suggests a key role for FBLN4 in the association of LTBP1 with microfibrils and the latent TGF-β cytokine. 89 Indeed, upregulated TGF-β signaling was found both in fibroblasts of cutis laxa patients with FBLN4 mutations and in the aortic wall of Fbln-4 hypomorphic mice (Figure) . 88 Interestingly, FBLN4 is also involved in recruiting lysyl oxidase to the elastic fiber, and lysyl oxidase is known to inhibit TGF-β enzymatically. 90 The gene responsible for the arterial tortuosity syndrome (OMIM 208050) is SLC2A10, 61 which codes for glucose transporter 10, a member of the facilitative glucose transporter family (Table 1) . Although it is still unclear what the substrate for this transporter is, a link to TGF-β signaling has been suggested (Figure) . By mechanisms that are not well understood, a deficiency of functional glucose transporter 10 protein leads to upregulation of TGF-β signaling, potentially mediated by altered expression of decorin, a known TGF-β antagonist. 61 In addition, and more recently, studies in zebrafish suggested that glucose transporter 10 is involved in cardiovascular development and that it functions through both stimulation of the mitochondrial respiratory chain and TGF-β signaling. 91 Another rare, autosomal dominant Marfan-like disorder, congenital contractual arachnodactyly (OMIM 121050), is caused by heterozygous mutations in FBN2 (Table 1) . 51 Patients with FBN2 mutations present with marfanoid features, including arachnodactyly, contractures, marfanoid body habitus, and mitral valve prolapse. Arterial aneurysms are not frequently observed in this condition. 92
Other Syndromic Forms of Aortic Aneurysmal Disease
TAA can also be an important complication of different subtypes of Ehlers-Danlos syndrome (EDS). EDS is a heterogeneous group of disorders with cutaneous (skin hyperextensibility, atrophic scars), skeletal (joint hypermobility and luxations), and vascular features (vascular rupture, easy bruising).
The most life-threatening form is the vascular type of EDS (former type 4 EDS, OMIM 130050), which is caused by a deficiency of type III collagen ( Table 1 ). The clinical phenotype is characterized by rupture of middle-sized arteries and intestines. 93 Aortic dissections have also been described and seem to occur without significant preceding aneurysm formation. Although it is known that collagen production is TGF-β dependent, there is no evidence that mutations in COL3A1 do affect TGF-β pathway regulation in a direct way. Nevertheless, Brooke 94 suggested that the celiprolol effect seen in vascular EDS treatment 95 might be related to its TGF-β expressionsuppressing effects. Alternatively, indirect cross-talk between bone morphogenetic protein and TGF-β signaling could contribute to further ECM degeneration. 96 Specific arginine-to-cysteine mutations in COL1A1 have been identified in a subset of affected individuals who typically present with aneurysms of the abdominal aorta and iliac arteries reminiscent of vascular EDS (Table 1) . 97 For these cases, distinct abnormalities on collagen electrophoresis have been observed.
The valvular type of EDS (OMIM 225320) is a rare form of EDS with early-onset cardiac valvular dysfunction. This autosomal recessive condition is caused by nonsense mutations in COL1A2. 64 Other recurrent findings include joint hypermobility and skin hyperextensibility. Borderline aortic root dilatations have been described.
Aortic aneurysm and arterial rupture can also occur in the kyphoscoliotic form of EDS (the former type VI or ocularscoliotic type, OMIM 225400). This generalized connective tissue disorder is characterized by kyphoscoliosis, joint laxity, muscle hypotonia, and, in some individuals, ocular problems. This autosomal recessive form of EDS is caused by deficient activity of the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (also called lysyl hydroxylase 1), and mutations in the encoding gene, PLOD1, are causative (Table 1) . 98 The diagnosis of kyphoscoliotic form of EDS relies on the demonstration of an increased ratio of deoxypyridinoline to pyridinoline crosslinks in urine. Alternatively, an assay of lysyl hydroxylase enzyme activity in skin fibroblasts is diagnostic.
Mildly dilated aortas have been described in the hypermobile form of EDS, but these do not seem to progress over time, and aortic dissection is almost never encountered in hypermobile EDS. 99 Finally, a spectrum of EDS-like findings has been associated with FLNA mutations ( Table 1) . Filamin A is an intermediate filament that connects the contractile apparatus of the VSMC to the cell membrane (Figure) . Filamin A has numerous interaction partners, including membrane receptors, transcription factors, and intermediate signaling proteins. 100, 101 Although FLNA mutations were initially associated with periventricular nodular heterotopias (OMIM 300049), more recently, patients with mitral valve disease, aortic root dilatation, and joint hypermobility without periventricular nodular heterotopias have been associated with FLNA mutations. 67 Occasionally, aortic root aneurysms have been described in other rare genetic syndromes (Online Table II ). Several other signaling pathways seem to be involved. First, aortic aneurysms have been described sporadically in patients with mutations involving the rat sarcoma-ERK signaling pathway, including Noonan syndrome (eg, PTPN11) 102,103 and neurofibromatosis (NF1). 104 This finding suggests links between these RASopathies and the noncanonical TGF-β signaling pathway involved in several common syndromic forms of aortic aneurysms, such as MFS and LDS. Second, the Notch signaling pathway has been implicated in the Alagille syndrome 105, 106 (see also section on bicuspid aortic valve [BAV]/ TAA). Third, aortic aneurysm has been occasionally implicated in several forms of hereditary hemorrhagic telangiectasia, caused by mutations in ENG, activin A receptor, type II-like 1 (ACVRL1), and SMAD4. [107] [108] [109] The latter genes either encode for components of the TGF-β signaling pathway (SMAD4) or for a receptor of the TGF-β superfamily of ligands (ENG, ACVRL1). Mainly, patients with mutations in SMAD4, associated with juvenile polyposis syndrome (OMIM 174900) and a combined juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia (OMIM 175050), were described to have TAA. 110 Fourth, mutations in other genes encoding collagens or enzymes involved in collagen maturation (COL1A1/A2, COL4A1, COL4A3/4/5, PLOD3) 63, [111] [112] [113] [114] [115] [116] [117] [118] have been associated with aortic aneurysm, but overall the incidence of aortic aneurysm in these disorders (osteogenesis imperfecta, hereditary angiopathy with nephropathy, aneurysms and muscle cramps syndrome, Alport syndrome) seems very low. Finally, an association of TAAD with autosomal dominant polycystic kidney disease (ADPKD) has been reported. In 1% to 10% of patients with ADPKD, aortic aneurysms are found. [119] [120] [121] Furthermore, dissection of the thoracic aorta is 7× more frequent in patients with ADPKD. 122 The causal ADPKD genes, PCD1 and PCD2, AAT indicates aortic aneurysm, familiar thoracic; AOVD1, aortic valve disease 1; BAV, bicuspid aortic valve; FAA, familia aortic aneurysms; FTAAD, familial thoracic aortic aneurysm and dissection; PDA, patent ductus arteriosus; SNP, single-nucleotide polymorphism; STAAD, sporadic thoracic aortic aneurysm and dissection; and TAAD, thoracic aortic aneurysm and dissection. encode for polycystines, which are transmembrane molecules. Interestingly, polycystin-1 has several ECM motifs that may function in cell-cell and cell-matrix interactions. 123 Finally, dysregulated TGF-β signaling has also been shown to be involved in the pathogenesis of ADPKD. 124
Nonsyndromic TAA: Components of the VSMC Contractile Apparatus… and Once Again TGF-β Dysregulation
Sporadic nonsyndromic TAA and dissections (sporadic TAAD[STAAD]) is a complex and multifactorial disease, mostly affecting the ascending aorta. 125 Twenty percent of patients with TAAD have affected family members, designated as FTAAD. The latter is usually inherited in an autosomal dominant fashion with variable expression and reduced penetrance. 126 STAAD occurs at a mean age of 66 years, whereas FTAAD cases are diagnosed at ≈56 years of age. 125 Several candidate loci for FTAAD have been found ( Table 2 ). The responsible gene for the TAAD2 locus (3p24-25) was shown to be TGFBR2. 75, 127 Indeed, mutations in TGFBR2 can cause a broad spectrum of disease, from nonsyndromic TAAD to full-blown LDS. Another LDS gene, SMAD3, can cause FTAAD as well, 82 whereas FBN1 mutations have also been identified in patients with FTAAD. 128 Many of the reported families present skeletal syndromic features and might represent the mildest end of the syndromic spectrum. This demonstrates the variable expression of symptoms caused by mutations in TAA genes, which may implicate the presence of modifying genes that may exaggerate or suppress the development of additional symptoms.
Besides the genes previously involved in syndromic types of TAA, several other genes have been implicated in nonsyndromic FTAAD. ACTA2 mutations are responsible for 14% of patients with FTAAD (Table 1 and Table 2 ). 68 The ACTA2 gene encodes a VSMC-specific isoform of the α-actin protein and is involved in VSMC contraction (Figure) . Other vascular manifestations caused by mutations in this gene include premature coronary artery disease and stroke. 141 Surprisingly, 1 specific ACTA2 missense mutation (p.Arg179His) also causes a generalized smooth muscle dysfunction with patent ductus arteriosus (OMIM 613834), which includes symptoms such as mydriasis, intestinal malrotation, hypotonic bladder, and periventricular white matter hyperintensities. It was shown that the ACTA2 p.Arg179His mutation alters the formin regulation of actin filament polymerization, resulting in filament instability. 142 Mutations in MYH11 are associated with FTAAD and patent ductus arteriosus (locus on 16p; Table 1 and Table 2 ). 70, 125 MYH11 encodes a myosin heavy chain, which is involved in VSMC contraction (Figure) . It should be noted, however, that many of the MYH11 mutations did not segregate within the TAAD/patent ductus arteriosus families. Thus, it is expected that additional modifying genetic factors contribute to the phenotype within these families. 143 Within the autosomal recessive Myh11 zebrafish model (meltdown; mlt), constitutive activation of the Myh11 ATPase part, which subsequently results in disruption of the VSMC surrounding the posterior intestine, leads to high mortality. These findings implicated that smooth muscle signaling could play an essential role in the maintenance of the epithelial wall. 144 Indeed, 1 TAAD patient with a mutation affecting the MYH11 ATPase part, the homologous region of the one affected in the mlt zebrafish, showed an early and severe decrease in the elasticity of the aortic wall. 69 The contraction of VSMC is initiated by phosphorylation of myosin light chains. This process is catalyzed by the myosin light chain kinase (MYLK), which in turn is activated by binding of calcium-calmodulin. MYLK is thus another key player in VSMC contraction. Building on the previous identification of 2 important components of the VSMC contractile apparatus (ACTA2 and MYH11), MYLK mutation analysis was performed in patients with FTAAD. 70 MYLK mutations were found in a minority of FTAAD cases (<1%). 145 Loss of MYLK function could lead to alteration of its calcium-calmodulin-binding capacity, which is required for MYLK activation and phosphorylation of myosin. Patients with MYLK mutations often develop aneurysms in the ascending thoracic aorta, which is the part of the aorta exposed to the highest biomechanical force. It has been suggested that MYLK haploinsufficiency may decrease the VSMC contractile function and that, as a consequence, the aorta will not be able to withstand the biomechanical forces for long. 70 Also, the absence of other VSMC problems in patients with mutations in components of the VSMC contractile apparatus demonstrates that the VSMC itself is not majorly affected and that aneurysms mainly develop at locations where the biomechanical forces are greatest. This may mean that one working allele might be sufficient for smooth muscle cell contraction but that it leaves the aortic wall in a weaker position.
Intriguingly, upregulation of TGF-β signaling has also been observed in the aortic walls of TAA patients with ACTA2 and MYH11 mutations. 146 This might not be completely surprising because the VSMC contractile apparatus is linked through the intermediate filaments to the cell surface integrins, which are known major regulators of TGF-β activity. These findings suggest a possible link between TGF-β upregulation and VSMC contractility alterations.
The genetic basis for STAAD has been explored as well. A first genome-wide association study was performed, which, surprisingly, identified a region of linkage disequilibrium that contained the FBN1 gene. Thus, it seems that common variation at the FBN1 locus may explain part of the susceptibility to aneurysm formation in STAAD. 134 Genome-wide copy number variant analysis in a large number of STAAD cases further suggested the involvement of VSMC adhesion and contraction in the development of TAA. 137, 138 
BAV-Associated TAA: Polygenic or Complex
Genetic Phenotype?
BAV (OMIM 109730) is the most common congenital heart disorder. Curiously, BAV often remains asymptomatic, but the risk of developing TAA is 9× higher in patients with BAV than in patients with a tricuspid aortic valve (TAV). Aneurysms most commonly occur in the ascending aorta distal to the sinotubular junction; however, dilatation can occur anywhere between the aortic root and the aortic isthmus. 29 Very little is known at the molecular level about the development of BAV and BAV-associated TAA, demonstrating the complexity of the disease. Although several linked loci have been identified (5q, 13q, 18q; Table 2 ) 139 and a set of candidate genes/proteins (ACTA2, TGFBR2, nitric oxide synthase 3, ubiquitin fusion degradation 1-like, etc) 52, [147] [148] [149] have been proposed, until now, mutations in only a single gene (NOTCH1) have been consistently associated with BAV. 71 NOTCH1 is a key component of the Notch signaling pathway, important in transcriptional regulation and in cell growth and differentiation. Notch signaling also promotes epithelial-mesenchymal transition during cardiac development. 150 Investigations on the role of Notch signaling in TAAD, more specifically in descending aneurysms, showed a complex signaling pattern, with activation in fibroblasts but impairment in medial VSMC. 151 Although studies have shown that TAA formation is different in BAV and TAV, 152 at least some disease mechanisms may be shared. Most interestingly, increased TGF-β activity was demonstrated in BAV-associated TAA. 153 BAV and TAV have slightly different mRNA expression profiles, as well as alternative splicing of genes involved in the TGF-β pathway. 154 In contrast to the TAV aortic aneurysms, BAV aneurysms were associated with a relative lack of inflammation, normal MMP9 levels, and elevated MMP2 expression. [155] [156] [157] Because the latter is an activator of TGF-β signaling, 158 this provides indirect evidence of the involvement of TGF-β dysregulation in the pathogenesis of BAV/TAA. Medial degeneration is also observed in BAV-associated dilated aortic tissue, including elastic fiber degeneration and fragmentation, noninflammatory VSMC loss, and accumulation of basophilic ground substance. 29 In women with Turner syndrome, aortic dilatation at the level of the sinuses of Valsalva has been reported in 25% of the patients with BAV and in 5% of the patients with TAV. 159 Genetic data suggest that the responsible gene most likely is located on the short arm of the X-chromosome ( Table 2 ).
Major Progress But Important Questions and Paradoxes Remain…
During the past decade, important questions regarding the pathogenetic basis of TAA have been solved. These discoveries have 3 important consequences. First, the pathogenesis of TAA(D) is better understood, although some controversy still exists. Second, management strategies for the treatment of TAA are becoming increasingly gene-tailored. Third, the pathogenetic insights have delivered new treatment options that are currently being investigated in large clinical trials.
A Better Understanding of Pathogenesis Has Engendered Controversy
With regard to the pathogenesis of TAA, 2 major themes have emerged. First, for the nonsyndromic forms of TAA, mutations in genes encoding major components (actin, myosin, etc) of the VSMC contractile apparatus are the connecting thread. Second, within the syndromic forms of TAA, involvement of the TGF-β signaling pathway has emerged as the key culprit. Interestingly, a recent study found evidence of dysregulated TGF-β signaling in aortic tissue derived from ACTA2 and MYH11 patients, including increased connective tissue growth factor and pSMAD2. 146 Although the exact pathogenic mechanism behind this increased TGF-β activity in tissue with a deficiency in VSMC contractility remains unclear, this implies once again that TGF-β signaling is a key element of TAA development.
Although it is clear that at the level of the aortic tissue increased TGF-β signaling is present in the different forms of TAA, the precise cellular mechanisms underlying this uprise remain elusive and have engendered some controversy in the field. In MFS, FBN1 mutations can lead to a disruption of the latent complex containing the inactive TGFB protein, which can thus be more easily released, hence resulting in an increased activation. For TGFBR1/2 mutations in LDS, it is becoming increasingly evident that, although the mutations in the serine/ threonine kinase domains of these proteins lead to a loss of function of the kinase activity, a complete haploinsufficiency of TGFBR1 or TGBFR2 does not seem to cause an aortic aneurysm phenotype. 160, 161 Furthermore, the currently described nonsense mutations in LDS are all predicted to escape nonsense-mediated decay, and true nonsense mutations in TGFBR1 cause a skin cancer phenotype, multiple self-healing squamous epithelioma. 162 As such, having some mutant protein expressed seems to be a prerequisite to cause an aortic aneurysm phenotype. However, nonsense mutations and complete deletions of SMAD3 and TGFB2 suggest that haploinsufficiency or complete loss of function of these genes would be the causal mechanism. However, when studying aortic wall tissue of patients with mutations in SMAD3 or TGFB2, a clear upregulation of TGF-β signaling was observed. 53, 54 These observations have created quite some controversy: despite a loss of function at the molecular level, a recurrent pattern of enhanced TGF-β signaling is observed at the aortic tissue level. Several possible explanations have been suggested for this paradox, but all of them need to be validated by further experimental evidence. One of the possible theories states that because of the mutations in the canonical components (TGFB2, SMAD3, TGFBR1/2) of the TGF-β signaling pathway, the noncanonical (ERK/mitogenactivated protein kinase) pathway aims to compensate for the loss of the canonical pathway, but that this finally results into an overcompensation. 1, 44 Alternatively, shifts between isoforms of the TGF-β cytokine might play a role. Preliminary evidence suggests that TGFB2-deficient patients and mice have an increased expression of TGFB1, causing a shift from TGFB2driven to TGFB1-driven signaling. 54 Finally, an important role has been assigned to the difference in embryological origin of the various cell types in the aortic root (eg, second heart field versus neural crest cells). A relative perturbation of TGF-β signaling is predicted to have a disproportionate effect on the more vulnerable lineage (second heart field), resulting in increased ligand expression and excessive TGF-β signaling by adjacent cells of a different lineage (cardiac neural crest), with relative preservation of signaling potential. 1 During the past years, other surprising observations have been made. Specific mutations in FBN1 can cause stiff skin syndrome (OMIM 184900) and geleophysic dysplasia (OMIM 614185), both of which show MFS-opposing manifestations, such as stiff skin and shorter limbs ( Table 1) . 49 Mutations are found in 2 hot spots: exons 37 and 38, which encode a domain containing an Arg-Gly-Asp motif (important in mediating cell-matrix interactions via integrin binding), and exons 41 and 42, which encode LTBP-like domains. 49, 50 Interestingly, in both conditions, an enhanced TGF-β signaling, similar to the one found in MFS, has been observed. How similar disturbance of TGF-β signaling can lead to quite opposite phenotypes (eg, shorter limbs in geleophysic dysplasia and long limbs in MFS) needs further investigation but clearly suggests tissue-and domain-specific functions of FBN1 with regard to its modulation of the TGF-β signaling. Further elucidation of all mechanisms regulating TGF-β signaling in bone will be a challenging task for the coming decade.
Toward Gene-Tailored Management Strategies
After the identification of different genes underlying TAA, a clinical management stratification based on the underlying gene is becoming increasingly important. For example, patients with LDS have an increased risk for developing aortic and arterial aneurysms beyond the aortic root and as such need more extensive imaging follow-up. 72 In patients with ACTA2 mutations, an increased incidence of coronary artery disease and premature strokes has been reported, and these patients might benefit from secondary prevention. 163 Similarly, the current guidelines of the American College of Cardiology recommend prophylactic surgery based on different scenarios according to the underlying gene 163 : (1) LDS patients with a mutation in TGFBR1 or TGFBR2 should be operated when the echocardiographic diameter of the ascending aorta reaches 40 to 42 mm in adults; patients with SMAD3 mutations will benefit from similar treatment guidelines, whereas the TGFB2 patients seem to have milder aortic disease; but the experience within the latter group is small and specific treatment guidelines will need more discussion; (2) patients with familial TAAD and mutations in MYH11 or ACTA2 should be operated when the diameter of the ascending aorta measures between 45 and 50 mm; (3) patients with familial TAAD with relatives experiencing an aortic dissection should be operated at a minimal dilatation of the thoracic aorta (<50 mm); although the numbers are still small, aortic dissections at minimal dilatation of the aorta have also been described in MYLK mutant patients 70 ; (4) for all other patients with TAAD, the American College of Cardiology recommends to operate when the ascending aorta or aortic root reaches a threshold of 50 mm, in case of rapid growth of the aorta (≥5 mm/y) and in the presence of severe aortic valve insufficiency or stenosis. During the past couple of years, the use of valve-sparing techniques has shifted the thresholds to lower limits (eg, 45 mm in MFS).
Novel Therapeutic Approaches
Until recently, the medical management strategy in TAA used MFS as a paradigm. Medical treatment aiming at reducing aortic wall stress consisted mostly of β-blocker treatment. 164 Alternatively, calcium channel blockers and angiotensinconverting-enzyme inhibitors have been used occasionally. 165 Since the initial discovery of the key role of TGF-β signaling in the pathogenesis of lung disease in Marfan mice, 41 the effect of TGF-β neutralizing treatment has been investigated thoroughly in different organ systems of the Marfan mice. 45, 46 In 2006, a TGF-β neutralizing antibody and the angiotensin II type I receptor antagonist losartan were observed to slow aortic root dilatation and elastic fiber fragmentation by reducing TGF-β signaling in Marfan mice. 46 Losartan was already an established drug for treatment of hypertension, which encouraged researchers to investigate this possible alternative treatment in Marfan patients. As the angiotensin pathway is in itself a regulator for the TGF-β pathway, losartan proved to diminish the accumulation of activated SMAD2 and also reduced expression of TGF-β-responsive genes. 1 Several human clinical trials are now ongoing to evaluate whether comparable positive results such as those previously observed in mice can be obtained. A preliminary study in a small cohort of severely affected Marfan patients showed the improved effectiveness by the reduced progression of aortic root dilatation of the losartan add-on β-blocker therapy in comparison with β-blocker therapy alone. 166 The largest clinical trial is currently assessing the efficacy of losartan compared with β-blocker therapy in >600 patients with MFS. 167 A first smaller trial on 28 patients has already been completed, showing that losartan add-on β-blocker therapy provides an increased protection compared with β-blocker-only therapy. 168 Because MFS is used as a model for nonsyndromic TAA, it is anticipated that TGF-β-targeting treatments will also benefit the latter group.
The increasing knowledge gathered during the past few years provides opportunities for promising research at genetic, molecular, and hemodynamic levels, which in turn leads to new ways of approaching therapies. With every new TAA gene identified, the hope for an effective therapy increases. As a result of the growing evidence of the involvement of the TGF-β pathway, this remains the main focus. Especially, treatments that aim to block the noncanonical components of the TGF-β signaling pathway (eg, ERK antagonists) are currently being investigated, although we should consider the importance of the VSMC contractile apparatus and the role of the Notch pathway in BAV too. 151 The role of MMPs has been cornered for treatment as well. Inhibitors of MMPs have an effect on vascular disease in animal models. 169 Another interesting approach consists of antagonizing the FBN1-derived GxxPG (Gly-x-x-Pro-Gly) fragments, which has also been shown to ameliorate disease in MFS mice. 170 Finally, talks of stem cell therapy have been initiated. 171 It was shown that multipotent stem cells are abundant in affected TAAD tissue and that differentiation to VSMC and fibroblasts is not uncommon. Stem cells might not only be involved in repair of medial degeneration tissue, but also in destructive modeling. As these are only preliminary data, additional research will be required to assess the role and behavior of stem cells in aortic tissue before we can develop any treatment strategies.
